Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer

New England Journal of Medicine

Volumn 336, Issue 6, 1997, Pages 404-409

  Fanucchi, Michael ^a   Glaspy, John ^b   Crawford, Jeffrey ^c   Garst, Jennifer ^c   Figlin, Robert ^b   Sheridan, William ^d   Menchaca, Dora ^d   Tomita, Dianne ^d   Ozer, Howard ^a   Harker, Laurence ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MACROGOL; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0031049879     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199702063360603     Document Type: Article

References (46)

1. Slichter SJ. Principles of platelet transfusion therapy. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principles and practice. New York: Churchill Livingstone, 1991:1610-22.
2. Menitove JE. Transfusion-transmitted diseases. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principles and practice. New York: Churchill Livingstone, 1991:1651-60.
3. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-8.
4. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mp1 ligand. Nature 1994;369: 533-8.
5. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-24.
6. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-4.
7. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-71.
8. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994;91:11104-8.
9. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem (Tokyo) 1995;118:229-36.
10. Hunt P, Li YS, Nichol JL, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995;86:540-7.
11. Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor: analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973-8.
12. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-30.
13. Choi ES, Hokom M, Bartley T, et al. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem Cells (Dayt) 1995;13: 317-22.
14. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994;265:1445-7.
15. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood 1996;87:2162-70.
16. de Sauvage FJ, Carver-Moore K, Luoh S-M, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651-6.
17. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996;87:5006-15.
18. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995;86: 4486-92.
19. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995;86:54-9.
20. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-21.
21. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996;97:2145-51.
22. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996;88:366-76.
23. Idem. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996;88:1509-14.
24. Foster D, Hunt P. The biological significance of truncated and full-length forms of Mpl ligand. In: Kuter DJ, Sheridan WP, Hunt P, Zucker-Franklin D, eds. Thrombopoiesis and thrombopoietins: molecular, cellular, preclinical and clinical biology. Totowa, N.J.: Humana Press, 1996:203-14.
25. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13: 1860-70.
26. Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Scmin Oncol 1995;22:Suppl 9:48-54
27. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
28. Miller AB, Hoogstraten B, Stagnet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
29. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1984.
30. Feld R, Ginsberg RJ, Payne DG, Shepherd FA. Lung. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology. New York: Churchill Livingstone, 1995:1083-152.
31. Smith JW II, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993;328:756-61.
32. Postmus PE, Gietema JA, Damsma O, et al. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol 1992;10:1131-40.
33. D'Hondt V, Humblet Y, Guillaume T, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: multicentric placebo-controlled, randomized phase Ib study. Blood 1995;85:2347-53.
34. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-24.
35. Vadhan-Raj S, Broxmeyer HE, Andreeff M, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995;86:2098-105.
36. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992;18:353-72.
37. Rogers JS II, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6:276-81.
38. Basser RL, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996;348: 1279-81.
39. O'Malley CJ, Rasko JEJ, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88:3288-98.
40. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52.
41. Toombs CF, Young CH, Glaspy JA, Varnum BC. Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. Thromb Res 1995;80:23-33.
42. Chen J, Herceg-Harjacek L, Groopman JE, Grabarck J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995;86:4054-62.
43. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993;91:1310-3.
44. Grabarek J, Groopman JE, Lyles YR, et al. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994;269: 21718-24.
45. Decoster G, Rich W, Brown SL. Safety profile of filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, eds. Filgrastim (r-metHuG-CSF) in clinical practice. New York: Marcel Dekker, 1994:267-90.
46. Glaspy J. Clinical applications of stem cell factor. Curr Opin Hematol 1996;3:223-9.